Exagen to Announce Second Quarter 2021 Financial Results on August 9, 2021

Rhea-AI Summary

Exagen Inc. (Nasdaq: XGN) will announce its financial results for Q2 2021 on August 9, 2021, post-market close. Key executives, including CEO Ron Rocca and CFO Kamal Adawi, will lead a conference call at 4:30 PM Eastern Time to review the results. Interested parties can join the call by phone or through a webcast available on Exagen’s investor relations website. A replay of the call will be accessible until August 16, 2021. Exagen focuses on autoimmune testing solutions, aiming to enhance patient care through its AVISE® brand products.

Positive

• Upcoming financial results announcement on August 9, 2021.
• Engagement of key executives in the financial results review.

Negative

• None.

SAN DIEGO, July 26, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2021 after the market close on Monday, August 9, 2021. Ron Rocca, Exagen’s President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company’s results at 4:30 PM Eastern Time (1:30 PM Pacific Time).

Interested parties may access the conference call by dialing (877) 407-3982 (U.S.) or (201) 493-6780 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at https://investors.exagen.com/

A replay of the conference call will be available until Monday, August 16, 2021 at 11:59 PM Eastern Time (8:59 PM Pacific Time). Interested parties may access the replay of the conference call by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) using passcode 13721307.   Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately 30 minutes after the call concludes.

About Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE^® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus. For further information please visit www.exagen.com.

CONTACTS:

Investor Relations

Exagen Inc.
Ryan Douglas
rdouglas@exagen.com
760.560.1525

Company Contact

Exagen Inc.
Kamal Adawi, Chief Financial Officer
KAdawi@exagen.com
760.477.5514

FAQ

What date will Exagen Inc. announce its financial results?

Exagen Inc. will announce its financial results on August 9, 2021.

Who will be hosting the Q2 2021 earnings call for Exagen?

The earnings call will be hosted by CEO Ron Rocca and CFO Kamal Adawi.

How can I access the Exagen Inc. earnings call?

You can access the earnings call by dialing designated phone numbers or via the webcast on Exagen's investor relations website.

When is the replay of Exagen's earnings call available until?

The replay of the earnings call will be available until August 16, 2021.

What is Exagen's primary focus in the healthcare sector?

Exagen specializes in autoimmune testing solutions to improve care for patients with chronic autoimmune diseases.